CA-CROWN-BIOSCIENCE
5.5.2021 14:32:06 CEST | Business Wire | Press release
Crown Bioscience (CrownBio), a JSR Life Sciences company and leader in preclinical services that help biopharmaceutical companies accelerate new drug development programs, has acquired OcellO B.V., a privately owned contract research organization located in the Netherlands. Through the acquisition, CrownBio will expand its portfolio of in vitro services, integrating OcellO’s expertise in high content imaging alongside CrownBio’s in vitro and in vivo screens and immunotherapy assessment services. Financial terms are not being disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210505005619/en/
“CrownBio and OcellO believe that the key to improving clinical research success is to utilize more patient-relevant models and assays that can generate reliable efficacy data as early as possible in the drug development process,” said Armin Spura, PhD, Chief Executive Officer of CrownBio . “This acquisition brings together the complementary strengths of our two companies, enhancing our in vitro services portfolio and offering customers the ability to better evaluate multiple drug combinations and targets, across a wider range of tumor and cancer types, with improved predictability and clinical relevance moving from in vitro to in vivo phases of drug discovery.”
The acquisition establishes CrownBio as the only global source licensed to offer customers specialized Hubrecht Organoid Technology (HUB) for drug development programs. Under the terms of the agreement, Leo Price, PhD, OcellO’s Chief Executive Officer and Chief Scientific Officer, will join CrownBio as Senior Vice President, In Vitro , to lead the Company’s in vitro business in the US and Europe.
“I am delighted to join CrownBio and help grow the company’s in vitro portfolio,” said Dr. Price. “We will continue our shared heritage of innovation and dedication to customer service to serve complex needs in early-stage cancer drug development. Our combined expertise is particularly suited for disease-relevant large-scale screening, allowing our customers to evaluate multiple drug combinations in a rapid, scientifically rigorous, and cost-effective way.”
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit: www.crownbio.com
About OcellO B.V.
OcellO is a leading provider of compound testing services using advanced organotypic human tissue models of cancer, inflammation, and polycystic kidney disease. Automated 3D cell culture technology is combined with high content 3D imaging and analysis in a robust platform that provides scalability without compromising biological complexity. Cancer drug discovery services utilize organoids, PDX- derived tumoroids and patient tumor-derived models representing most solid tumor types and incorporating different components of the immune system.
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20210505005619/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vara Receives World-First CE Certification for Autonomous AI in Breast Cancer Screening2.9.2026 08:00:00 CEST | Press release
Vara has received CE certification under the EU Medical Device Regulation (Class IIb) for autonomous triage in organised breast cancer screening – the first breast AI certified anywhere to report screening examinations as normal without radiologist review. In autonomous triage, examinations the system classifies as clearly normal can be reported by AI without a radiologist reading them; every other examination continues to be read by at least one radiologist. This deployment mode is intended for organised population screening, where a shrinking radiologist workforce is straining programmes that still read every mammogram twice. The certification has only been possible because Vara has developed a safety system that supervises the autonomous use of its AI models. "What made this possible is not the AI model alone," said Stefan Bunk, CTO and co-founder of Vara. "It is based on seven years of continuous monitoring of how our AI performs in the real world, on every single case. That experi
Phison Expands European Operations with Regional Office and Executive Appointments2.9.2026 08:00:00 CEST | Press release
Phison Electronics (8299TT), a global leader in NAND flash controllers and storage solutions, today announced the expansion of its European operations with the opening of its inaugural local entity in Eschborn, Germany, and the appointments of Ingvar Ersson as GM & President, EMEA, and Antony Zukowski as Regional Director, EMEA, for Phison Electronics Europe GmbH. The expansion strengthens Phison's investment in Europe and reinforces its commitment to supporting customers and partners as demand for AI infrastructure, enterprise storage and next-generation data center technologies continues to grow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901302026/en/ The extended organization will execute a regional go-to-market strategy that combines direct enterprise engagement with a focused ecosystem of distributors, system integrators and strategic partners to accelerate adoption of Phison's Pascari enterprise SSD portfolio.
Goku Technologies Chooses SS&C for Fund Services2.9.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that Singapore Goku Technologies Pte. Ltd., an AI-driven quantitative investment manager, has chosen SS&C as its fund services provider. The firm, with offices in Shanghai and Singapore, employs systematic trading strategies to invest in equities across Asia, with USD4 billion in assets under management. SS&C GlobeOp will provide fund administration services for the Goku Technologies Master Fund. The fund operates a high-volume trading strategy with substantial daily trading activity. SS&C will support the fund through a comprehensive suite of services including fund accounting and investor services, helping Goku Technologies build a scalable operating model. “As our business has grown, so have our demands on our trading and operational framework,” said Ken Chung, CEO of Singapore Goku Technologies. “We are building an institutional quality operations infrastructure, so we needed a provider capable of supporting a high-vol
Boomi Delivers the Critical Infrastructure That Brings Control to Enterprise AI2.9.2026 03:00:00 CEST | Press release
Govern AI agents, optimize token spend, and mitigate security risk to operationalize AI at scale Boomi, the data activation company for AI, today announced major platform innovations designed to solve critical barriers to enterprise AI adoption. At the core of these updates is Boomi’s Agent Control Plane, AI-native infrastructure that securely connects AI agents to core business systems, provides governance over agent activity, and controls runaway AI costs. This critical infrastructure runs flexibly across public cloud, the customer’s own cloud (VPC), or on-premises, directly supporting data and digital sovereignty, and giving organizations greater operational control over their AI estate. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260901851538/en/ Boomi Delivers the Critical Infrastructure That Brings Control to Enterprise AI Key Takeaways Boomi’s Agent Control Plane provides the critical AI-native infrastructure that
Meraki Capital Launches Tessero Across Six European Markets Following Landmark Hays Acquisition1.9.2026 22:36:00 CEST | Press release
Meraki Capital has launched Tessero,a new European specialist recruitment group created from the six former Hays plc businesses it acquired earlier this summer. Launching simultaneously across Sweden, Denmark, Hungary, Romania, Luxembourg and Czechia, Tessero brings six established recruitment businesses together under one independent European brand, creating an international platform with experienced teams, existing clients and active candidate networks from day one. The launch follows one of the most significant transactions in Meraki Capital’s history and the completion of a major transition programme across all six countries within weeks of the acquisition. 130 employees will now operate under the Tessero brand, with established country leadership teams remaining in place and continuing to lead their respective markets. Gary Elden OBE, CEO of Meraki Capital and Director of Tessero, said: “Tessero launches with something that normally takes years to build: established businesses, ex
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom